Thrombospondin 1 expression and angiogenesis in breast carcinoma and their relation with platelet activity

Figures & data

Figure 1.  Correlation between platelet counts and tumour size.

Figure 2.  Platelet counts in the patients who had microvessel density (MVD) grade 1, grade 2, and grade 3.

Table I.  Results of the blood and tissue analysis of the groups.

	Control	Patient
Platelet count (1000/mm^3)	236.79±12.84	281.35±17.12^a
Platelet TxB2 (ng /mL)	76.43±10.37	84.50±6.63
Platelet cGMP (pmol /mL)	1.42±0.20	0.85±0.11^a

Data presented as the mean±standard error of mean.

^a P < 0.05 as compared with that of control group.

Figure 3.  A: Cytoplasmic thrombospondin (TSP) staining with a granular texture in tumour cells and fibrillary staining in the stroma juxtaposed to tumour cells (×200). B: Fibrillary TSP staining in the tumour stroma (×40).

Figure 4.  Thrombospondin (TSP)-positive macrophages adjacent to tumour cells (×400).

Figure 5.  Immunohistochemical staining for endothelial cells with CD34, representative example of microvessel density (MVD) grade.

Table II.  Histopathological and immunohistochemical findings of the 20 cases of breast carcinoma.

			MVD			Tumour Cell TSP staining		Stromal TSP staining		TSP-positive stromal macrophages
Parameters studied	Mean age (y)	Patients (n)	1+	2+	3+	0	1	0	1	<10%	≥10%
Tumour size
≤ 2 cm	60	12 (60%)	6 (30%)	4 (20%)	2 (10%)	9 (45%)	3 (15%)	5 (25%)	7 (35%)	8 (40%)	4 (20%)
> 2 cm	51	8 (40%)	4 (20%)	2 (10%)	2 (10%)	6 (30%)	2 (10%)	6 (30%)	2 (10%)	5 (25%)	3 (15%)
Histological grade ^a
1	55	14 (70%)	7 (35%)	5 (25%)	2 (10%)	11 (55%)	3 (15%)	9 (45%)	5 (25%)	9 (45%)	5 (25%)
2	60	6 (30%)	3 (15%)	1 (5%)	2 (10%)	4 (20%)	2 (10%)	2 (10%)	4 (20%)	4 (20%)	2 (10%)
In situ component
Negative	61	11 (55%)	7 (35%)	3 (15%)	1 (5%)	8 (40%)	3 (15%)	5 (25%)	6 (30%)	7 (35%)	4 (20%)
Positive	51	9 (45%)	3 (15%)	3 (15%)	3 (15%)	7 (35%)	2 (10%)	6 (30%)	3 (15%)	6 (30%)	3 (15%)
Vascular invasion
Negative	57	16 (80%)	8 (40%)	4 (20%)	4 (20%)	12 (60%)	4 (20%)	8 (40%)	8 (40%)	11 (55)	5 (25%)
Positive	54	4 (20%)	2 (10%)	2 (10%)		3 (15%)	1 (5%)	3 (15%)	1 v(5%)	2 (10%)	2 (10%)
Status of axillary lymph nodes
Negative	59	8 (40%)	2 (10%)	4 (20%)	2 (10%)	6 (30%)	2 (10%)	4 (20%)	4 (20%)	5 (25%)	3 (15%)
Positive	55	12 (60%)	8 (40%)	2 (10%)	2 (10%)	9 (45%)	3 (15%)	7 (35%)	5 (25%)	8 (40%)	4 (20%)
Extranodal spread
Negative	55	7 (35%)	5 (25%)	1 (5%)	1 (5%)	5 (25%)	2 (10%)	4 (20%)	3 (15%)	4 (20%)	3 (15%)
Positive	47	5 (25%)	3 (15%)	1 (5%)	1 (5%)	4 (20%)	1 (5%)	3 (15%)	2 (10%)	4 (20%)	1 (5%)
Status of ER
Negative	58	9 (45%)	5 (25%)	1 (5%)	3 (15%)	7 (35%)	2 (10%)	5 (25%)	4 (20%)	7 (35%)	2 (10%)
Positive	55	11 (55%)	5 (25%)	5 (25%)	1 (5%)	8 (40%)	3 (15%)	6 (30%)	5 (25%)	6 (30%)	5 (25%)
Status of PR
Negative	58	11 (55%)	4 (20%)	3 (15%)	4 (20%)	8 (40%)	3 (15%)	6 (30%)	5 (25%)	8 (40%)	3 (15%)
Positive	55	9 (45%)	6 (30%)	3 (15%)		7 (35%)	2 (10%)	5 (25%)	4 (20%)	5 (25%)	4 (20%)

^a There are no grade 3 cases.